Company intelligence / Profile preview

Cytosurge

Glattbrugg, Zurich, Switzerlandcytosurge.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cytosurge is a synthetic biology enabler specializing in patented single-cell bottom-up gene editing processes and dynamic gene expression analysis. Their FluidFM platform allows precise manipulation of individual cells for applications such as CRISPR engineering, mechanobiology studies, temporal transcriptomics, and more. The company’s CellEDIT service supports the creation of advanced genetically engineered mammalian cell lines to accelerate next-generation therapies. Cytosurge does not have its own clinical pipeline but empowers academic and industry partners to advance their research using its technologies

Modalities: Device (FluidFM technology)CRISPR-based gene editing (enabling technology, not a therapeutic developer)
Industry: Non-Drug Biotech

Partnerships

ETH Zurich

Beyond the preview

Go deeper on Cytosurge.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytosurge.

Explore the full profile